Publikasi Scopus FKUI 2021 per tanggal 31 Maret 2021 (187 artikel)

Pranata R., Lim M.A., Yonas E., Vania R., Lukito A.A., Siswanto B.B., Meyer M.
57201973901;57216039756;57201987097;57208328436;57213835420;14422648800;57217373886;
Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis
2021
Diabetes and Metabolism
47
2
101178
32
Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Vania, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Lukito, A.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia, Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia; Siswanto, B.B., Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Meyer, M., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
Background: There is mounting evidence related to the association between obesity and severity of COVID-19. However, the direct relationship of the increase in the severe COVID-19 risk factors, with an increase in body mass index (BMI), has not yet been evaluated. Aim: This meta-analysis aims to evaluate the dose–response relationship between body mass index (BMI) and poor outcome in patients with COVID-19. Methods: A systematic literature search was conducted using PubMed, Europe PMC, ProQuest, and the Cochrane Central Database. The primary outcome was composite poor outcome composed of mortality and severity. The secondary outcomes were mortality and severity. Results: A total of 34,390 patients from 12 studies were included in this meta-analysis. The meta-analysis demonstrated that obesity was associated with composite poor outcome (OR 1.73 [1.40, 2.14], P < 0.001; I2: 55.6%), mortality (OR 1.55 [1.16, 2.06], P = 0.003; I2: 74.4%), and severity (OR 1.90 [1.45, 2.48], P < 0.001; I2: 5.2%) in patients with COVID-19. A pooled analysis of highest BMI versus reference BMI indicate that a higher BMI in the patients was associated with composite poor outcome (aOR 3.02 [1.82, 5.00], P < 0.001; I2: 59.8%), mortality (aOR 2.85 [1.17, 6.92], P = 0.002; I2: 79.7%), and severity (aOR 3.08 [1.78, 5.33], P < 0.001; I2: 11.7%). The dose–response meta-analysis showed an increased risk of composite poor outcome by aOR of 1.052 [1.028, 1.077], P < 0.001 for every 5 kg/m2 increase in BMI (Pnon-linearity < 0.001). The curve became steeper with increasing BMI. Conclusion: Dose–response meta-analysis demonstrated that increased BMI was associated with increased poor outcome in patients with COVID-19. © 2020 Elsevier Masson SAS
Body mass index; Coronavirus; Obesity; SARS-CoV-2; Weight
antidiabetic agent; antihypertensive agent; adult; aged; antihypertensive therapy; Article; body mass; clinical outcome; coronavirus disease 2019; diabetes mellitus; disease severity; dose response; female; human; hypertension; male; meta analysis; mortality rate; obesity; risk assessment; systematic review
Elsevier Masson s.r.l.
12623636
32738402
Article
Q1
1429
2421